Status Of Current ResearchWelcome to Advanced Respiratory Technologies, Inc.
Advanced Respiratory Technologies Inc. is a medical technology company dedicated to providing better treatment options for patients suffering from serious forms of respiratory and pulmonary disease. Our Company is focused on the development and commercialization of technologies that treat a wide range of respiratory diseases and certain injuries that prevents the lung from properly absorbing oxygen and eliminating carbon dioxide and debris.
Our flagship technology is known as “Transient Liquid Ventilation” (TLV). Transient Liquid Ventilation represents a potentially safer and more effective method of directly treating acute and infectious forms of respiratory disease and to support other important applications, such as drug delivery. TLV delivers oxygen through the use of a novel device, developed by the Company. The device controls the entire treatment, including the circulation of a unique super-oxygenated liquid (Perflurocarbon or PFC) to and from the lungs, monitors the patient's progress and removes carbon dioxide and debris from the respiratory system. Accordingly, our initial objective is to seek the regulatory approval of Transient Liquid Ventilation in the treatment of the following disease indications and patient populations:
- Low birth weight infants born prematurely, suffering from Neonatal Respiratory Disease Syndrome (NRDS).
- Adults inflicted with Acute Respiratory Disease Syndrome (ARDS) and Acute Lung Injury (ALI)
Advanced Respiratory Technologies, Inc. has also in-licensed a patented technology involving the mixture of oxygen and helium, known as Heliox, which is used in the treatment of certain forms of obstructive respiratory/pulmonary diseases.
The Company's technologies and products address the treatment of patients in the hospital intensive care and home-health care environments who require ventilation support. Lung and pulmonary disorders affect 41 million Americans, at an annual cost of more than $30 billion, more than is spent on the treatment of hypertension, stroke, osteoarthritis, kidney and infectious diseases. Additionally, respiratory diseases cause more deaths annually than breast cancer and AIDS. Respiratory disease is currently one of the three leading causes of death in the U.S.
Indications also point to a staggering rise in the incidence of respiratory and pulmonary diseases in many countries outside of the U.S., due to a number of economic, environmental and social factors. Respiratory disease is one of the leading causes of death throughout entire the world. In many countries, respiratory disease and related lung injuries result in a higher number of mortalities than any other form of disease, affecting people of all age groups; from premature infants to elderly adults alike. For instance in China, it is estimated that respiratory disease accounts for more than 20% of all deaths and is the leading cause of mortality. Various health agencies point to an alarming increase in the incidence of serious and often fatal forms of respiratory disease throughout the world.